Seng dan Respons Imun pada Talasemia

Teny Tjitra Sari

Sari


Infeksi merupakan morbiditas dan mortalitas yang penting pada pasien talasemia. Mekanisme terjadinya infeksi yang berperan adalah gangguan respons imun akibat patofisiologi penyakit talasemia, kelebihan besi, splenektomi dan defisiensi seng. Seng merupakan zat penting pada respons imun yang dihubungkan dengan akivitas timulin. Kadar feritin yang tinggi juga memengaruhi kadar seng pada pasien talasemia. Suplementasi seng memperbaiki kadar seng yang berakibat pada perbaikan stres oksidatif dan respons imun
pada pasien talasemia. 

 


Kata Kunci


seng; respons imun; talasemia

Teks Lengkap:

PDF

Referensi


Rund D, Rachmilewitz E. β-thalassemia. N Engl J Med 2005;353:1135-46.

Eleftheriou A. About thalassemia. Cyprus: Thalassemia International Federation; 2007.h. 38-76.

Taher A, Vichinsky E, Musallam K, Cappellini MD, Viprakasit V. Guidelines for the management of non transfusion dependent thalassaemia (NTDT). Cyprus: Thalassemia International Federation; 2013. h. 2.

Data Register Pusat Thalassaemia RSCM Jakarta, tidak dipublikasikan.

Ezer Ü, Gülderen F, çulha VK, Akgül N, Gürbüz Ö. Immunological status of thalassemia syndrome. Pediatr Hematol Oncol 2002;19:51-8.

Vento S, Cainelli F, Cesario F. Infections and thalassemia. Lancet Infect Dis. 2006;6:226-33.

Chern JPS, Su S, Lin KH, Chang SH, Lu MY, Jou ST, dkk. Survival, mortality and complications in patients with β-thalassmia major in Northern Taiwan. Pediatr Blood Cancer 2007;48:550-4.

Wiener E. Impaired phagocyte antibacterial effector functions in β-thalassemia: a likely factor in the increased susceptibility to bacterial infections. Hematology 2003;8:35-40.

Ricerca BM, Di Girolamo A, Rund D. Infections in thalassemia and hemoglobinopathies: focus on therapyrelated complications. Mediterr J Hematol Infect Dis. 2009;1:e2009028. Diunduh tanggal 15 Februari 2012. Didapat dari: www.mjhid.org/article/view/5229.

Shaiegan M, Abdee J, Zaman-Vaziree M, Khajehian A. Comparison of neutrophil function in patients with thalassemia major and healthy controls. Arch Iranian Med 2002;5:175-8.

Pattanapanyasat K, Sukapirom K, Tachavanich K, Kaewmoon S. Flow cytometric quantitation of opsonophagocytosis and intracellular killing of Candida albicans using a whole blood microassay. Cytometry 2007;71A:1027-33.

Gangemi S, Merendino RA, Meo A, Minciullo PL, Briuglia S, Merlino MV, dkk. Serum levels of interleukin-18 in splenectomized and nonsplenectomized thalassemic patients: preliminary considerations.

Acta Haematol 2003;110:45-7.

Öztürk O, Yaylim I, Aydin M, Yilmaz H, Ağaçhan B, Demiralp E, dkk. Increased plasma levels of interleukin-6 and interleukin-8 in β-thalassemia major. Haematologia 2001;31:237-44.

Cunningham-Rundles S, Giardi na PJ, Grady RW, Califano C, McKenzie P, De Sousa M. Effect of transfusional iron overload on immune response. JID 2000;182:S115-21.

Gharagozloo M, Karimi M, Amirghofran Z. Doublefaced cell-mediated immunity in β-thalassemia major: stimulated phenotype versus suppressed activity. Ann Hematol 2009;88:21-7.

Dore F, Bonfigli S, Pardini S, Longinotti M. Serum interleukin-8 levels in thalassemia intermedia. Haematologica 1995;80:431-3.

Wanachiwanawin W. Infection in E-β thalassemia. J Pediatr Hematol Oncol 2000;22:581-7.

Mosthtaghi-Kashanian GR, Gholamhoseinian A, Hoseinmoghadam A, Rajabalian S. Splenectomy changes the pattern of cytokine production in β-thalassemic patients. Cytokine 2006;35:253-7.

Atasever B, Kuruca SE, Karakas Z, Agaoglu L. In vitro modulation of cellular immunity with antioxidants in patients with thalassemia major. Blood (ASH Annual Meeting Abstracts). 2004;104:Abstract 3775.

Walker EM, Walker SM. Effects of iron overload on the immune system. Ann Clin Lab Sci 2000;30:354-65.

Wang SC, Lin KH, Chern JPS, Lu MY, Jou ST, Lin DT, dkk. Severe bacterial infection in transfusiondependent patients with thalassemia major. Clin Infect Dis 2003;37:984-8.

Baratawidjaja KG, Rengganis I. Imunologi dasar. Edisi ke-11. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2014.h.41-745.

Sakran W, Levin C, Kenes Y, Colodner R, Koren A. Clinical spectrum of serious bacterial infections among splenectomised patients with hemoglobinopathies in Israel: a 37-year follow-up study. Infection 2012;40:35-9.

Ahluwalia J, Datta U, Marwaha RK, Sehgal S. Immune functions in splenectomized thalassaemic children. Indian J Pediatr 2000;67:871-6.

Cunningham-Rundles S, Giardina PJ, Grady RW, Califano C, McKenzie P, De Sousa M. Effect of transfusional iron overload on immune response. JID 2000;182:S115-21.

Kiani-amin M, Mohammadmehdi D, Parviz A, Shima M, Nima R. Serum immunoglobulin levels in splenectomized and non-splenectomized patients with major beta-thalassemia. Iranian J Pediatr 2011;21:95-8.

Vergin C, Kutukculer N, Cetingul N, Nisli G, Caglayan S, Oztop S. Serum immuno-globulins, IgG subclasses, isohemagglutinins and complement-3 levels in patients with thalassemia major. Indian J Pediatr 1997;64:215-9.

Dardenne M. Zinc and immune function. Eur J Clin Nutr 2002;56:S20-3.

Fraker PJ, King LE, Laakko T, Vollmer TL. The dynamic link between the integrity of the immune system and zinc status. J Nutr 2000;130:S1399-1406.

Ibs KH, Rink L. Zinc-altered immune function. J Nutr 2003;133:S1452-6.

Consolini R, Calleri A, Legitimo A, Massei F. Immunological

evaluation of patients with beta-thalassemia major. Acta Haematol 2001;105:7-12.

Arijanty L, Nasar SS, Madiyono B, Gatot D. Relationships between plasma zinc and ferritin with nutritional status in thalassemic children. Paediatr Indones 2006;46:220-4.

Rashidi M, Aboomardani M, Rafraf M, Arefhosseini SR, Keshtkar A, Joshaghani H. Effects of vitamin E and zinc supplementation on antioxidants in beta thalassemia major patients. Iran J Pediatr 2011;21:8-14.

Tienboon P. Effect of nutrition support on immunity in paediatric patients with beta-thalassaemia major. Asia Pacific J Clin Nutr 2003;12:61-5.

Bartakke S, Bavdekar SB, Kondurkar P, Muranjan MN, Manglani MV, Sharma R. Effect of deferiprone on urinary zinc excretion in multiply transfused children with thalassemia major. Indian Pediatr 2005;42:150-4.

Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaogiu L, dkk. A phase 3 study of deferasirox (ICL670), a once-daily iron chelator in patients with β-thalassemia. Blood 2006;107:3455-62.

Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, dkk. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005;90:1309-14.

Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, dkk. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006;91:1241-3.

Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, dkk. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron

in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-84.




DOI: http://dx.doi.org/10.14238/sp18.2.2016.157-63

Refbacks

  • Saat ini tidak ada refbacks.


##submission.copyrightStatement##

##submission.license.cc.by-nc-sa4.footer##

Informasi Editorial:
Badan Penerbit Ikatan Dokter Anak Indonesia
Jl. Salemba I No 5, Jakarta 10430, Indonesia
Phone/Fax: +62-21-3912577
Email: editorial [at] saripediatri.org

Lisensi Creative Commons
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.